Related Experiment Videos
Special patient populations: onychomycosis in the HIV-positive patient
1Department of Dermatology, Albany Medical College, New York, USA.
Abstract:
Superficial fungal infections, including onychomycosis, have become an increasing problem as the number of patients with HIV infection or AIDS has grown. Superficial fungal infections and other cutaneous and noncutaneous disorders are correlated with a decline in the patient's CD4 cell count and are markers of disease progression. For those HIV-positive patients with fungal nail infections, the introduction of the new triazole antifungal agents (e.g., itraconazole, fluconazole) has markedly improved the therapeutic outcome. Unlike traditional topical or oral antifungal therapies, whose clinical utility was limited by relatively poor efficacy and the need for prolonged treatment, the new triazoles fulfill one of the foremost goals of HIV-infected patients: rapid symptomatic improvement of onychomycosis. For many patients, particularly those who live in areas with a high incidence of HIV, the psychologic rewards associated with the alleviation of this unsightly and "telltale" condition are immeasurable.
Insights
New triazole antifungals offer rapid relief for superficial fungal infections like onychomycosis in HIV-positive patients. These agents significantly improve therapeutic outcomes and patient quality of life compared to older treatments.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Superficial fungal infections, notably onychomycosis, are increasingly prevalent in patients with Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS).
- These infections, along with other cutaneous and noncutaneous disorders, correlate with declining CD4 cell counts and serve as indicators of disease progression in HIV-infected individuals.
Purpose of the Study:
- To evaluate the efficacy of novel triazole antifungal agents in managing superficial fungal infections, specifically onychomycosis, in the context of HIV infection.
- To compare the therapeutic outcomes of new triazole antifungals with traditional antifungal therapies for HIV-positive patients.
Main Methods:
- The study focuses on the clinical application and outcomes of new triazole antifungal agents (itraconazole, fluconazole) for superficial fungal infections in HIV-positive patients.
- Comparison is made against traditional topical or oral antifungal treatments regarding efficacy and treatment duration.
Main Results:
- New triazole antifungals, including itraconazole and fluconazole, have demonstrated markedly improved therapeutic outcomes for fungal nail infections in HIV-positive patients.
- These agents provide rapid symptomatic improvement of onychomycosis, addressing a key patient goal.
Conclusions:
- The introduction of new triazole antifungal agents represents a significant advancement in treating superficial fungal infections, particularly onychomycosis, in HIV-infected individuals.
- These newer agents offer superior efficacy and faster symptom relief compared to older treatments, leading to substantial psychologic benefits for patients.